Oak Therapeutics earned a competitive Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health to advance its innovative treatment for tuberculosis (TB). Oak is developing oral dissolvable strips (ODS) that deliver Rifapentine and Isoniazid, the two main medications used for TB. Unlike pills, the thin strips dissolve on the tongue without water, offering a portable, patient-friendly alternative designed to improve treatment adherence.
“Tuberculosis remains one of the world’s deadliest infectious diseases, especially in places where treatment options are scarce,” said Ed Maliski, Ph.D., the CEO and CSO of Oak. “By making TB treatment easier to take and distribute, Oak aims to help patients complete therapy, reduce drug resistance and ultimately, save lives.”
The SBIR Phase II funding, totaling $1.8 million over two years, will allow Oak Therapeutics to:
- Optimize the ODS formulations of Rifapentine and Isoniazid for stability, scalability and consistent dosing.
- Conduct preclinical trials to prepare for human trials.
- Build a manufacturing pathway to produce the strips cost-effectively at scale.
“This grant accelerates our work from lab innovation to real-world impact,” said Gerhard Apfelthaler, Ph.D., Oak’s chief strategy and administrative officer. “Our goal is to create a dissolvable TB treatment that can be used anywhere, from major hospitals to rural clinics, without sacrificing effectiveness.”
With NIH support, Oak Therapeutics is positioning its ODS platform for the next stage of development and eventual FDA approval, potentially transforming how TB is treated worldwide.
About Oak Therapeutics
Oak Therapeutics is a biopharmaceutical innovator focused on making medicine simpler, safer and more accessible. Its proprietary oral dissolvable strip (ODS) technology delivers precise doses without the need for water or swallowing pills. Oak is advancing its ODS platform across multiple therapeutic applications, including TB, HIV, dry mouth, and more. With locations at KU Innovation Park in Lawrence, Kan. and in Westlake Village, Calif., the company is redefining patient experience and access in modern medicine. Learn more about Oak at https://www.oaktherapeutics.com/.
This press release refers to NIH project number 2R44AI179391-02.



















